Sun Life and Medzown Partner to Bridge Clinical Trial Access

The collaboration leverages Medzown’s precision medicine platform to identify patients at critical diagnostic crossroads. According to Sun Life’s 2026 high-cost claims report, cancer treatment averages $252,000 per individual annually, while musculoskeletal conditions cost roughly $120,000. Medzown’s predictive analytics will now serve as a proactive tool for Sun Life clients to detect these high-cost cases early.

Once a candidate is identified, a team of precision medicine scientists and personal navigators coordinates directly with the patient and their care team to facilitate clinical trial enrollment. Jennifer Collier, president of Health and Risk Solutions at Sun Life U.S., noted that the initiative addresses both the human and financial dimensions of major health conditions. For employers, this adds another layer to existing cost-containment efforts, moving beyond traditional stop-loss coverage toward active clinical intervention. Dr. Jennifer Levin Carter, founder and CEO of Medzown, emphasized that the model acts as an extension of existing benefits, ensuring that members navigating life-changing diagnoses have access to every available medical intervention.